Alison Ehrlich is a Dermatology physician. OpenAlex indexes 105 publications with 2,272 citations (h-index 25); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5530 Wisconsin Ave Ste 530
Chevy Chase, MD 208154451
Telephone
202-838-3016Provider last certified this registry record 5 Feb 2025.
Clinical trials
- Photodynamic Therapy for Papulopustular Rosacea
Sponsor: George Washington University
- Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis
Sponsor: George Washington University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20253 payments
- ABBVIE INC.Program year20253 payments
- Amgen Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.1%Corticosteroid34.1%Fluocinonide100%Part D≥18 patientsDermatology
29.7%Interleukin-4 Receptor alpha Antagonist17.6%Dupixent Pen100%Part D<11 patientsCorticosteroid12.1%Triamcinolone Acetonide100%Part D<11 patientsAnti-infectives
24.2%Nitroimidazole Antimicrobial12.1%Metronidazole100%Part D<11 patientsAzole Antifungal12.1%Ketoconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Quaternary Ammonium Compounds and Contact Dermatitis: A Review and Considerations During the COVID-19 Pandemic
Clinical Cosmetic and Investigational Dermatology
2023 - Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy
Arthritis & Rheumatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”